Home GPCR & G Protein Glucagon Receptor chemical Teduglutide For research use only.

Teduglutide

Synonyms: ALX-0600, Gattex, Revestive, TAK 633

Teduglutide (ALX-0600, Gattex, Revestive, TAK 633) is an analogue of human glucagon-like peptide-2 (GLP-2) and binds to the GLP-2 receptors. Teduglutide prolongs the intestinotrophic properties of GLP-2 in animal models.

Teduglutide Chemical Structure

Teduglutide Chemical Structure

CAS No. 197922-42-2

Purity & Quality Control

Teduglutide Related Products

Biological Activity

Description Teduglutide (ALX-0600, Gattex, Revestive, TAK 633) is an analogue of human glucagon-like peptide-2 (GLP-2) and binds to the GLP-2 receptors. Teduglutide prolongs the intestinotrophic properties of GLP-2 in animal models.
In vitro
In vitro

Teduglutide increases Caco-2 proliferation but tends to inhibit intestinal epithelial differentiation[4]. 
Cell Research Cell lines Human Caco-2 intestinal epithelial cells
Concentrations 500 nM
Incubation Time 72 h
Method

Caco-2 cells (10 000 cells per 96-well plate) are plated in cell culture medium for 24 hours. The next day, the cells are incubated with 500nM teduglutidein serum-free medium for 72 hours. Then the cells are harvested for cell proliferation assay, bromodeoxyuridine incorporation assay and cell cycle analysis.
In Vivo
In vivo

In the Short bowel syndrome (SBS) situation, teduglutide not only maximizes small intestinal mucosal hypertrophy but also partially restores small intestinal epithelial function through an altered distribution of claudin-10, facilitating sodium recirculation for Na-coupled glucose transport and water absorption[3].
Animal Research Animal Models Short bowel syndrome model mice (C57BL6/J; male)
Dosages 0.1 mg/kg
Administration i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04883606 Completed
Short Bowel Syndrome
Takeda
 January 26 2022 --
NCT04344717 Recruiting
Short Bowel Syndrome|Anticoagulation
Universitaire Ziekenhuizen KU Leuven
 December 20 2020 Phase 4
NCT04733066 Unknown status
Short Bowel Syndrome|Intestinal Failure
Charite University Berlin Germany|Takeda
 September 1 2020 --
NCT03860688 Unknown status
Hyperlipidemias
University Health Network Toronto
 May 1 2019 Phase 2|Phase 3
NCT03442972 Completed
Hyperlipidemias
University Health Network Toronto|Kensington Screening Clinic
 January 17 2019 Phase 2|Phase 3

Chemical Information & Solubility

Molecular Weight 3752.08 Formula

C164H252N44O55S
CAS No. 197922-42-2 SDF --
Smiles CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(CC1=C[NH]C2=CC=CC=C12)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC(=O)C(CC(N)=O)NC(=O)C(CCSC)NC(=O)C(CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(O)=O)NC(=O)CNC(=O)C(N)CC5=CN=C[NH]5)C(C)O)C(C)CC)C(C)CC)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(C(C)O)C(=O)NC(CC(O)=O)C(O)=O
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 100 mg/mL ( (26.65 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Teduglutide | Teduglutide ic50 | Teduglutide price | Teduglutide cost | Teduglutide solubility dmso | Teduglutide purchase | Teduglutide manufacturer | Teduglutide research buy | Teduglutide order | Teduglutide mouse | Teduglutide chemical structure | Teduglutide mw | Teduglutide molecular weight | Teduglutide datasheet | Teduglutide supplier | Teduglutide in vitro | Teduglutide cell line | Teduglutide concentration | Teduglutide nmr